SomnoMed (ASX:SOM) LT-Debt-to-Total-Asset : 0.25 (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is SomnoMed LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. SomnoMed's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.25.

SomnoMed's long-term debt to total assets ratio declined from Dec. 2022 (0.32) to Dec. 2023 (0.25). It may suggest that SomnoMed is progressively becoming less dependent on debt to grow their business.

SomnoMed LT-Debt-to-Total-Asset Historical Data

The historical data trend for SomnoMed's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SomnoMed LT-Debt-to-Total-Asset Chart

SomnoMed Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

0.13

0.12

0.09

0.34

SomnoMed Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.11	0.09	0.32	0.34	0.25

SomnoMed LT-Debt-to-Total-Asset Calculation

SomnoMed's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jun. 2023 is calculated as

LT Debt to Total Assets (A: Jun. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Jun. 2023 )	/	Total Assets (A: Jun. 2023 )
	=	20.941	/	62.491
	=	0.34

SomnoMed's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	15.687	/	63.917
	=	0.25

SomnoMed (ASX:SOM) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

SomnoMed LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of SomnoMed's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

SomnoMed (ASX:SOM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » SomnoMed Ltd (ASX:SOM) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

SOMNF:USA RJV:Germany

Address

20 Clarke Street, Level 3, Crows Nest, Sydney, NSW, AUS, 2065

Website

https://www.somnomed.com/au

SomnoMed Ltd produces and sells oral treatment of sleep-related disorder devices. It manufactures and designs premium oral appliances for the treatment of sleep-disordered breathing relieving conditions. Its products include SomnoDent, Som Tabs, Som Morning Repositioner and others. Its geographical segments include North America, Europe, and Asia-Pacific. Business operations consist of the production and sale of products treating sleep-disordered breathing, which is the only reportable segment. Substantial revenue is realized from the European region.

SomnoMed (ASX:SOM) Headlines

No Headlines